Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

The effect of different terror exposures on the course of schizophrenia: A twenty-year follow-up of a random sample.

Weinstein Y, Gelkopf M, Roe D, Levine SZ.

Schizophr Res. 2017 Feb 14. pii: S0920-9964(17)30075-0. doi: 10.1016/j.schres.2017.02.004. [Epub ahead of print] No abstract available.

PMID:
28214174
2.

Holocaust exposure and subsequent suicide risk: a population-based study.

Bursztein Lipsicas C, Levav I, Levine SZ.

Soc Psychiatry Psychiatr Epidemiol. 2017 Mar;52(3):311-317. doi: 10.1007/s00127-016-1323-3. Epub 2016 Dec 28.

PMID:
28032138
3.

Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial.

Madhoo M, Levine SZ.

Eur Neuropsychopharmacol. 2016 Nov;26(11):1768-1774. doi: 10.1016/j.euroneuro.2016.09.368. Epub 2016 Oct 1.

PMID:
27707535
4.

Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials.

Levine SZ, Leucht S.

Schizophr Res. 2016 Dec;178(1-3):17-22. doi: 10.1016/j.schres.2016.09.002. Epub 2016 Sep 9.

PMID:
27617414
5.

Transgenerational effects of genocide exposure on the risk and course of schizophrenia: A population-based study.

Levine SZ, Levav I, Pugachova I, Yoffe R, Becher Y.

Schizophr Res. 2016 Oct;176(2-3):540-5. doi: 10.1016/j.schres.2016.06.019. Epub 2016 Jul 9.

PMID:
27401532
6.

A strengths-based case management service for people with serious mental illness in Israel: A randomized controlled trial.

Gelkopf M, Lapid L, Werbeloff N, Levine SZ, Telem A, Zisman-Ilani Y, Roe D.

Psychiatry Res. 2016 Jul 30;241:182-9. doi: 10.1016/j.psychres.2016.04.106. Epub 2016 Apr 30.

PMID:
27179184
7.

Genocide Exposure and Subsequent Suicide Risk: A Population-Based Study.

Levine SZ, Levav I, Yoffe R, Becher Y, Pugachova I.

PLoS One. 2016 Feb 22;11(2):e0149524. doi: 10.1371/journal.pone.0149524. eCollection 2016 Feb 22.

8.

Initial severity and efficacy of risperidone in autism: Results from the RUPP trial.

Levine SZ, Kodesh A, Goldberg Y, Reichenberg A, Furukawa TA, Kolevzon A, Leucht S.

Eur Psychiatry. 2016 Feb;32:16-20. doi: 10.1016/j.eurpsy.2015.11.004. Epub 2016 Jan 21.

PMID:
26802979
9.

Exposure to genocide and the risk of schizophrenia: a population-based study.

Levine SZ, Levav I, Goldberg Y, Pugachova I, Becher Y, Yoffe R.

Psychol Med. 2016 Mar;46(4):855-63. doi: 10.1017/S0033291715002354. Epub 2015 Dec 1.

PMID:
26619765
10.

Study of resilience and environmental adversity in midlife health (STREAM).

Velthorst E, Reichenberg A, Rabinowitz J, Levine SZ.

Soc Psychiatry Psychiatr Epidemiol. 2015 Dec;50(12):1915-22. doi: 10.1007/s00127-015-1126-y. Epub 2015 Oct 13.

11.

Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance.

Levine SZ, Rabinowitz J, Uher R, Kapur S.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1578-85. doi: 10.1016/j.euroneuro.2015.06.008. Epub 2015 Jun 20. Review.

PMID:
26145487
12.

Initial Severity Effects on Residual Symptoms in Response and Remission: A STAR*D Study During and After Failed Citalopram Treatment.

Madhoo M, Levine SZ.

J Clin Psychopharmacol. 2015 Aug;35(4):450-3. doi: 10.1097/JCP.0000000000000354.

PMID:
26066336
13.

Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.

Levine SZ, Goldberg Y, Samara M, Davis JM, Leucht S.

Schizophr Res. 2015 May;164(1-3):122-6. doi: 10.1016/j.schres.2015.02.021. Epub 2015 Mar 16.

PMID:
25790904
14.

The diagnostic criteria and structure of catatonia.

Wilson JE, Niu K, Nicolson SE, Levine SZ, Heckers S.

Schizophr Res. 2015 May;164(1-3):256-62. doi: 10.1016/j.schres.2014.12.036. Epub 2015 Jan 13.

PMID:
25595653
15.

Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.

Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S.

JAMA Psychiatry. 2015 Jan;72(1):14-21. doi: 10.1001/jamapsychiatry.2014.2127.

PMID:
25372935
16.

The effects of pre-natal-, early-life- and indirectly-initiated exposures to maximum adversities on the course of schizophrenia.

Levine SZ, Levav I, Yoffe R, Pugachova I.

Schizophr Res. 2014 Sep;158(1-3):236-40. doi: 10.1016/j.schres.2014.07.003. Epub 2014 Jul 21.

PMID:
25059202
17.

Suicide attempts in a national population of twins concordant for psychoses.

Levine SZ, Goldberg Y, Yoffe R, Pugachova I, Reichenberg A.

Eur Neuropsychopharmacol. 2014 Aug;24(8):1203-9. doi: 10.1016/j.euroneuro.2014.05.014. Epub 2014 Jun 6.

PMID:
24969308
18.

How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses.

Marques TR, Levine SZ, Reichenberg A, Kahn R, Derks EM, Fleischhacker WW, Rabinowitz J, Kapur S.

Eur Neuropsychopharmacol. 2014 Aug;24(8):1279-88. doi: 10.1016/j.euroneuro.2014.04.001. Epub 2014 Apr 24.

PMID:
24862257
19.

Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.

Levine SZ, Leucht S.

Schizophr Res. 2014 Jun;156(1):107-14. doi: 10.1016/j.schres.2014.04.005. Epub 2014 Apr 29.

PMID:
24794879
20.

Low birth-weight and risk for major depression: a community-based longitudinal study.

Levine SZ.

Psychiatry Res. 2014 Mar 30;215(3):618-23. doi: 10.1016/j.psychres.2014.01.008. Epub 2014 Jan 15.

PMID:
24485407

Supplemental Content

Loading ...
Support Center